Subthalamic nucleus

MeiraGTx Announces Third Quarter 2023 Financial and Operational Results

Retrieved on: 
Tuesday, November 14, 2023
CNS, DSM-IV codes, DNA, Conditional sentence, Janssen Pharmaceuticals, Subthalamic nucleus, Patient, Research, ESGCT, FTD, Capsid, Quality control, Congress, I&I, Safety, Treatment, IND, Immunology, Inherited disorders of trafficking, ROFN, Evercore, Genome, STN, Central nervous system, Martin Lipton, Frontotemporal dementia, Xerostomia, Johnson & Johnson, MIA, GMP, Gene, BLA, Commercial, Insurance, Parotid gland, ALS, Parkinson's disease, Clinical trial, Obesity, QC, File, CGMP, RIX, Pharmaceutical industry, Vaccine, Cryptocurrency, Birth control, Sanofi, Janssen, Inflammation

Bota-vec for the Treatment of XLRP:

Key Points: 
  • Bota-vec for the Treatment of XLRP:
    Enrollment completed in second quarter 2023 in the pivotal Phase 3 LUMEOS clinical trial in collaboration with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company.
  • In September 2023, the IND for bota-vec for the treatment of XLRP was transferred from MeiraGTx to Janssen.
  • Results from AQUAx Phase 1 open-label, dose-escalation study of gene therapy with AAV2-hAQP1 as a treatment for RIX and parotid gland hypofunction presented at ESGCT 2023 Annual Congress on October 26, 2023.
  • License revenue was $5.1 million for the quarter ended September 30, 2023, compared to $4.8 million for the quarter ended September 30, 2022.

Surgical Information Sciences Initiates VISION Study to Support Deep Brain Stimulation for Parkinson's Disease Patients

Retrieved on: 
Thursday, November 2, 2023
DBS, Physician, SIS, Deep brain stimulation, Research, GPI, STN, Surgeon, Subthalamic nucleus, Globus pallidus, Parkinson's disease, Hartford Hospital, Medical imaging, Patient, Disease

EDINA, Minn., Nov. 2, 2023 /PRNewswire/ -- Surgical Information Sciences, a medical device company focused on improved visualization of brain structures for deep brain stimulation (DBS) surgery, announced the commencement of its post-market study, the Visualization of the STN and GPi for DBS Surgery in Patients with Parkinson's Disease (VISION Study).

Key Points: 
  • EDINA, Minn., Nov. 2, 2023 /PRNewswire/ -- Surgical Information Sciences, a medical device company focused on improved visualization of brain structures for deep brain stimulation (DBS) surgery, announced the commencement of its post-market study, the Visualization of the STN and GPi for DBS Surgery in Patients with Parkinson's Disease (VISION Study).
  • This study aims to evaluate the potential of SIS technology in enhancing the accuracy of DBS implant placement for patients battling Parkinson's Disease.
  • The VISION Study will involve the participation of 90 patients across multiple sites, and it represents a significant step in the pursuit of improved treatment for those living with this challenging condition.
  • Dr. Patrick Senatus, a neurosurgeon at Hartford Hospital in Hartford, CT, commented, "The VISION Study presents an opportunity to assist surgeons and programming physicians in treating patients with Parkinson's Disease.

INBRAIN Neuroelectronics Announces FDA Breakthrough Device Designation for Its Graphene-Based Intelligent Network Modulation Platform

Retrieved on: 
Tuesday, September 19, 2023
Neurology, FDA, Medical Devices, Health, Health Technology, BCI, Multimedia, Steel, Carbon, Biomarker, Science, DBS, BDD, Neuropsychiatric Disease and Treatment, Stanford University School of Medicine, Patient, Subthalamic nucleus, STN, Neuro, Breakthrough, Pharmaceutical industry, Medical imaging, Medical device

, a health-tech company dedicated to developing the world’s first intelligent graphene-neural platform, today announced that its Intelligent Network Modulation System has been granted Breakthrough Device Designation (BDD) from the U.S. Food & Drug Administration (FDA) as an adjunctive therapy for treating Parkinson’s disease.

Key Points: 
  • , a health-tech company dedicated to developing the world’s first intelligent graphene-neural platform, today announced that its Intelligent Network Modulation System has been granted Breakthrough Device Designation (BDD) from the U.S. Food & Drug Administration (FDA) as an adjunctive therapy for treating Parkinson’s disease.
  • The thinnest material known, yet stronger than steel, graphene’s unique combination of electrical and mechanical properties makes it ideal for neurotechnology innovation.
  • “Breakthrough device designation from the FDA signifies the potential of the INBRAIN neural platform to further improve the lives of patients with Parkinson’s disease,” said INBRAIN Neuroelectronics Clinical Affairs Head Dan Gnansia.
  • “INBRAIN’s new generation of ultrathin graphene-based high resolution interfaces and associated network platform may vastly improve the precision, efficiency and efficacy of DBS and closed-loop or adaptive modulation.

MeiraGTx Reports Second Quarter 2023 Financial and Operational Results

Retrieved on: 
Thursday, August 10, 2023
GMP, DNA, ARVO, Insurance, Pros, Gene, QC, Clinical trial, Xerostomia, Research, CAR, Parkinson's disease, Patient, CGMP, Treatment, Annual general meeting, Subthalamic nucleus, Association for Research in Vision and Ophthalmology, Commercial, STN, Safety, IND, BLA, Medical imaging, Vaccine, Pharmaceutical industry, Fine chemical, Environmental remediation, Cryptocurrency, Janssen, Ophthalmology

“Progress across our programs and infrastructure continues to be extremely impressive,” said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx.

Key Points: 
  • “Progress across our programs and infrastructure continues to be extremely impressive,” said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx.
  • “This includes further advancement of our three lead clinical programs, our riboswitch gene regulation technology platform, and our manufacturing platform.
  • Cash and cash equivalents were $92.8 million as of June 30, 2023, compared to $115.5 million as of December 31, 2022.
  • License revenue was $3.5 million for the quarter ended June 30, 2023, compared to $10.8 million for the quarter ended June 30, 2022.

MeiraGTx Reports First Quarter 2023 Financial and Operational Results

Retrieved on: 
Thursday, May 11, 2023
GMP, ARVO, Insurance, Riboswitch, Growth hormone, Cerberus Capital Management, PIPE, Clinical trial, Adage Capital Management, Brain, Research, Cell, AAV, Parkinson's disease, Patient, CGMP, Endocrine gland, Treatment, Annual general meeting, Subthalamic nucleus, Association for Research in Vision and Ophthalmology, STN, RPGR, Safety, IND, Gene, BLA, Pharmaceutical industry, Vaccine, Cryptocurrency, Janssen, Ophthalmology

On track for BLA submission of botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of X-linked retinitis pigmentosa (XLRP) in 2024

Key Points: 
  • On track for BLA submission of botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of X-linked retinitis pigmentosa (XLRP) in 2024
    LONDON and NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial and operational results for the first quarter ended March 31, 2023, and provided a corporate update.
  • In May 2023, MeiraGTx closed the previously announced private investment in public equity (PIPE) financing, raising approximately $60 million in aggregate gross proceeds.
  • Cash and cash equivalents were $68.8 million as of March 31, 2023, compared to $115.5 million as of December 31, 2022.
  • License revenue was $3.3 million for the quarter ended March 31, 2023, compared to $5.6 million for the quarter ended March 31, 2022.

ClearPoint Neuro Extends Software License and Research Agreement with Philips to Include Fully Automatic Subnuclei Segmentation for DBS

Retrieved on: 
Tuesday, April 11, 2023
Learning, CT, Surgeon, Paper, VIM, GPI, Brain, Research, DBS, MRI, Thalamus, Journal, Patient, Machine learning, ANT, Subthalamic nucleus, Journal of Neurotrauma, Philips, STN, Neuro, FDA, Software, Medical imaging, Maestro

The design goal of the ClearPoint Maestro® Brain Model is to enable highly accurate ClearPoint interventions under both MRI and CT guidance by facilitating patient-specific, multi-modal fusion for accurate target identification and trajectory planning.

Key Points: 
  • The design goal of the ClearPoint Maestro® Brain Model is to enable highly accurate ClearPoint interventions under both MRI and CT guidance by facilitating patient-specific, multi-modal fusion for accurate target identification and trajectory planning.
  • “Extending our software collaboration with Philips beyond the subcortical brain regions in Maestro to include segmentation of subnuclei from MRI is key to our planned expansion into the operating room,” commented Joe Burnett, President and CEO of ClearPoint Neuro.
  • The unique methodology of the brain model combines deformable surfaces with active shape models and machine learning.
  • Maestro was FDA cleared in 2022 and is currently in limited market release at select U.S. academic medical centers and in pharmaceutical clinical trials.

French Neurosurgeon and Physicist Dr. Alim Louis Benabid, Recipient of 42nd Honda Prize, Honored at Online Award Ceremony

Retrieved on: 
Thursday, December 16, 2021
Electrode, Honda, Brain, Movement, Subthalamic nucleus, Deep brain stimulation, Pleasure, Prize, DBS, Research, Neurosurgery, Patient, Disease, Quality of life, Honda Prize, Dystonia, Parkinson's disease, Medical device

TOKYO, Dec. 16, 2021 /PRNewswire/ -- The Honda Foundation, based in Tokyo, is pleased to announce that the 42nd Honda Prize Award Ceremony was held on Wednesday, November 17, 2021, and awarded this year's prize to Dr. Alim Louis Benabid, emeritus professor at the Joseph Fourier University and chairman of the Edmond J. Safra Biomedical Research Center at Clinatec. Like last year, the award ceremony was held online, and was streamed live across the globe including Japan and France.

Key Points: 
  • Since its efficacy was demonstrated in clinical trials, over 150,000 patients across the world have had the surgery.
  • In recognition of this great achievement that this prize aims to honor, we awarded it to Dr. Benabid this year."
  • It is a great pleasure and honor to be awarded the Honda Prize and I am very grateful.
  • This aids in restoring movement functions, and curbing tremors and other symptoms for improved mobility in everyday living.

Honda Prize 2021 Awarded to French Neurosurgeon and Physicist Dr. Alim Louis Benabid

Retrieved on: 
Thursday, September 30, 2021
Deep brain stimulation, Joseph Fourier University, Parkinson's disease, Pharmacotherapy, CV, Subthalamic nucleus, Patient, Honda Prize, Tremor, Honda, Electrode, Board, Dystonia, Prize, DBS, Research, Motor disorder, Brain, Quality of life, Movement, Lists of diseases, Medical device

TOKYO, Sept. 30, 2021 /PRNewswire/ -- The Honda Foundation, the public interest incorporated foundation established by Soichiro Honda and his younger brother Benjiro and currently led by President Hiroto Ishida, is pleased to announce that the Honda Prize 2021 will be awarded to Dr. Alim Louis Benabid, Professor Emeritus of Joseph Fourier University and Chairman of the Board of Clinatec, both of France, for his contribution to pioneering research and practical application of deep brain stimulation (DBS) to the treatment of involuntary movement caused by progressive Parkinson's disease and other neurological disorders.

Key Points: 
  • DBS is a surgical procedure in which electrodes are implanted in the subthalamic nucleus in the brain.
  • The Prize will be awarded to Dr. Benabid for this innovative treatment method, which is worthy of the highest recognition.
  • This year, the presentation ceremony for the 42nd Honda Prize will be held on November 17, 2021, in an online format, to be broadcast in Japan, France and various other countries.
  • For more information about the press release and CV of Dr. Benabid, please refer to the Honda Foundation via: URL: https://www.hondafoundation.jp/news/view_en/1504

Surgical Information Sciences Announces First Commercial Use of Recently Cleared Software for Improved Visualization of Brain Targets

Retrieved on: 
Monday, May 3, 2021
Basal ganglia, Branches of biology, Neuroscience, Anatomy, Internal globus pallidus, Subthalamic nucleus, External globus pallidus, Globus pallidus, GPE, Cortico-basal ganglia-thalamo-cortical loop

The SIS System uses deep learning models to identify brain structures such as the subthalamic nuclei (STN) and globus pallidus internus/externus (GPi/GPe) commonly targeted for DBS procedures.

Key Points: 
  • The SIS System uses deep learning models to identify brain structures such as the subthalamic nuclei (STN) and globus pallidus internus/externus (GPi/GPe) commonly targeted for DBS procedures.
  • The SIS System provides visualization of these structures for surgical planning and for location of the implanted DBS leads and lead contacts post-surgery.\nThe STN and GPi/GPe are key targets for patients with Parkinson\'s disease.
  • Despite advances in imaging, the STN and GPi/GPe anatomy are too small to be accurately visualized with today\'s imaging capabilities.
  • SIS is more accurate than standard surgical planning programs I\'ve used, and leaves no doubt as to where the target structure is located.

Multicenter, Deep Brain Stimulation Study Suggests Increased Range of Effective Stimulus Amplitude Using Directional vs. Omnidirectional Leads

Retrieved on: 
Friday, September 11, 2020
Medicine, Clinical medicine, Neurotechnology, Electrotherapy, Medical devices, Brain, Neuroprosthetics, Subthalamus, Deep brain stimulation, Subthalamic nucleus

MILWAUKEE, Sept. 11, 2020 /PRNewswire-PRWeb/ --A study released today at the MDS Virtual Congress 2020 examines the therapeutic window of stimulus amplitude between directional and omnidirectional leads used in deep brain stimulation.

Key Points: 
  • MILWAUKEE, Sept. 11, 2020 /PRNewswire-PRWeb/ --A study released today at the MDS Virtual Congress 2020 examines the therapeutic window of stimulus amplitude between directional and omnidirectional leads used in deep brain stimulation.
  • Leads are implanted in the brainspecifically, the subthalamic nucleus in the study presented here and connected to a programmable pulse generator.
  • Here, a double-blind, randomized comparison study examined the therapeutic window (TW) for both directional and the omnidirectional DBS leads.
  • Over 90% of participants experienced an increased TW, averaging near 40%, with the directional leads relative to the omnidirectional leads.